Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-10-2008 | Focus on

Oesophageal cancer: can imaging improve its assessment?

Author: Giovanni Lucignani

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 10/2008

Excerpt

Oesophageal cancer is the sixth most common cause of cancer death worldwide. Its incidence in 2002 was 462,117, with a male/female ratio of approximately 2:1. Occurrence of this disease increases with age and is highest in the age group 50–70 years. …

Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5. version 2.0, IARC Press, Lyon, 2004 http://www-dep.iarc.fr/

National Cancer Institute http://www.cancer.gov/cancertopics/types/esophageal/

National Cancer Institute http://planning.cancer.gov/disease/Esophageal-Snapshot.pdf

National Cancer Institute http://researchportfolio.cancer.gov/

Staging of oesophageal cancer. Cancer Imaging. 2007 Oct 1;7 Spec No A:S63–6. Review

Gines A, Cassivi SD, Martenson JA Jr, Schleck C, Deschamps C, Sinicrope FA, et al. Impact of endoscopic ultrasonography and physician specialty on the management of patients with esophagus cancer. Dis Esophagus 2008;21(3):241–50.PubMedCrossRef

Westerterp M, Sloof GW, Hoekstra OS, Ten Kate FJ, Meijer GA, Reitsma JB, et al. 18FDG uptake in oesophageal adenocarcinoma: linking biology and outcome. J Cancer Res Clin Oncol 2008;134(2):227–36. Feb.PubMedCrossRef

Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al. Recommendations on the use of ¹⁸F-FDG PET in oncology. J Nucl Med 2008;49(3):480–508. Mar.PubMedCrossRef

Miyata H, Doki Y, Yasuda T, Yamasaki M, Higuchi I, Makari Y, et al. Evaluation of clinical significance of 18F-fluorodeoxyglucose positron emission tomography in superficial squamous cell carcinomas of the thoracic esophagus. Dis Esophagus 2008;21(2):144–50.PubMedCrossRef

10.

McDonough PB, Jones DR, Shen KR, Northup PG, Galysh RL, Hernandez A, et al. Does FDG-PET add information to EUS and CT in the initial management of esophageal cancer? A prospective single center study. Am J Gastroenterol 2008;103(3):570–4. Mar.PubMedCrossRef

11.

van Westreenen HL, Westerterp M, Sloof GW, Groen H, Bossuyt PM, Jager PL, et al. Limited additional value of positron emission tomography in staging oesophageal cancer. Br J Surg 2007;94(12):1515–20. Dec, cancer.PubMedCrossRef

12.

Pfau PR, Perlman SB, Stanko P, Frick TJ, Gopal DV, Said A, et al. The role and clinical value of EUS in a multimodality esophageal carcinoma staging program with CT and positron emission tomography. Gastrointest Endosc 2007;65(3):377–84. Mar.PubMedCrossRef

13.

Katsoulis IE, Wong WL, Mattheou AK, Damani N, Chambers J, Livingstone JI. Fluorine-18 fluorodeoxyglucose positron emission tomography in the preoperative staging of thoracic oesophageal and gastro-oesophageal junction cancer: a prospective study. Int J Surg 2007;5(6):399–403. Dec.PubMedCrossRef

14.

van Vliet EP, Heijenbrok-Kal MH, Hunink MG, Kuipers EJ, Siersema PD. Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer 2008;98(3):547–57. Feb 12.PubMedCrossRef

15.

Vinjamuri S, Ray S. Added value of PET and PET-CT in oesophageal cancer: a review of current practice. Nucl Med Commun 2008;29(1):4–10. Jan.PubMedCrossRef

16.

Mamede M, El Fakhri G, Abreu-e-Lima P, Gandler W, Nosé V, Gerbaudo VH. Pre-operative estimation of esophageal tumor metabolic length in FDG-PET images with surgical pathology confirmation. Ann Nucl Med 2007;21(10):553–62. Dec.PubMedCrossRef

17.

Konski AA, Cheng JD, Goldberg M, Li T, Maurer A, Yu JQ, et al. Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with oesophageal carcinoma. Int J Radiat Oncol Biol Phys 2007;69(2):358–63. Oct 1.PubMed

18.

Bruzzi JF, Munden RF, Truong MT, Marom EM, Sabloff BS, Gladish GW, et al. PET/CT of esophageal cancer: its role in clinical management. Radiographics 2007;27(6):1635–52. Nov-Dec.PubMedCrossRef

19.

Chang EY, Li X, Jerosch-Herold M, Priest RA, Enestvedt CK, Xu J, et al. The evaluation of esophageal adenocarcinoma using dynamic contrast-enhanced magnetic resonance imaging. J Gastrointest Surg 2008;12(1):166–75. Jan.PubMedCrossRef

Title: Oesophageal cancer: can imaging improve its assessment?
Author: Giovanni Lucignani
Publication date: 01-10-2008
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 10/2008
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-008-0884-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Oesophageal cancer: can imaging improve its assessment?

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 10/2008

Selective hepatic arterial infusion of In-111-DTPA-Phe1-octreotide in neuroendocrine liver metastases

Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET–CT: a comparative study

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors

Tetrafluorophenolate of HBED-CC: a versatile conjugation agent for 68Ga-labeled small recombinant antibodies

Section of Nuclear Medicine of the European Union of Medical Specialists (UEMS) and European Board of Nuclear Medicine (EBNM)

Therapy options for treatment of hepatic malignancy